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Abstract 
Aims: We assessed changes of serum combined free immunoglobulin light chains (cFLC) 
levels, which are associated with increased all-cause mortality, in ST-elevation myocardial 
infarction (STEMI) in relation to inflammation and renal function indices. 
Methods: cFLC were measured in 48 patients with STEMI on days 1, 3, 7 and 30 with 
assessment of their relationships with monocyte subsets, high sensitivity C-reactive protein 
(hsCRP), and cystatin C. Day 1 levels in STEMI patients were compared to 40 patients with 
stable coronary artery disease, and 37 healthy controls.  
Results: There were no significant differences in cFLC levels between the study groups. In 
STEMI patients, cFLC values peaked on day 7 post-MI and remained elevated on day 30 
(p<0.001 vs. day 1 for both). hsCRP concentrations peaked on day 3 of STEMI followed by 
their gradual reduction to the levels seen in the controls (p<0.001). In STEMI cFLC 
correlated with cystatin C (r=0.55, p<0.001), and negatively correlated with counts of 
CD14++CD16– monocytes (r=-0.55, p<0.001). On multivariate Cox regression analysis, 
cFLC concentrations were associated with increased need for future percutaneous coronary 
intervention (PCI) (p=0.019). 
Conclusion: cFLC levels increase during STEMI with peak values on day 7 after presentation 
and predict the need for future PCI. 
 
Key words: free light chains, heart failure, coronary artery disease, ST-elevation myocardial 
infarction 
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Introduction 
 
The biological significance of the adaptive immune system is complex and spreads far 
beyond just infection control.[1-4] The paramount role of the innate immune system in 
cardiovascular pathology is very well established with involvement of 
monocytes/macrophages in atherogenesis and post-injury tissue remodelling being classical 
examples.[5-7] However, limited data are available on the role of the adaptive immune 
system in cardiac pathophysiology. Lymphocytes have been found to be involved in 
atherosclerotic plaque formation, but their low (rather than high) counts are typically 
associated with poor outcome, for example in heart failure.[5, 8-10] Lymphocyte derived 
biomarkers, such as immunoglobulin free light chains (FLC) which are produced in excess 
during antibody production and released into the circulation, may help investigation of the 
adaptive immune response. [11] 
 
Monoclonal generation of FLC κ and λ is a well-known parameter of plasma cell disorders, 
such as myeloma.[12] Until recently, limited information was available on polyclonal 
combined FLC (cFLC, summation of FLC κ and λ) elevations, when there is no obvious 
predominance of either chain. Polyclonal rise of cFLC predominantly reflects activation and 
proliferation of B-lymphocytes, although it could be also secondary to their impaired removal 
by dysfunctional kidneys or reticulo-endothelial system.[13, 14] Elevation of polyclonal 
cFLC has been reported in inflammatory and autoimmune disorders, diabetes mellitus and 
chronic kidney disease.[15-18] Also, high cFLC concentrations are associated with activity of 
autoimmune disorders characterised by B-cell activation, with clearly distinct kinetics for 
cFLC and a C-reactive protein (CRP), a marker predominantly related to inflammatory 
responses of innate immunity.[17, 19, 20] cFLC may thus be of clinical value as a biomarker 
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of the adaptive immunity state. Of note, both the innate and adaptive parts of the immune 
system work in close interaction.[21] Monocytes and their functional subsets represent a 
major cellular part of the innate immune system, but limited data are available on their 
relationship with cFLC.[22] 
 
High cFLC concentrations are highly predictive of mortality in the general population even 
after adjustment for age, gender and renal function.[23, 24] Raised cFLC were associated 
with cardiovascular mortality in patients with chronic kidney disease after accounting for 
CRP levels.[20] Given the pathophysiological relationships discussed above, this biomarker 
might be related to prognosis in patients with myocardial infarction (MI), there are no data on 
changes in cFLC in patients with MI at present. 
 
In the present pilot study, we aimed to assess dynamic changes of cFLC levels in STEMI 
patients over 30 days and their relation to markers of innate immunity (monocyte subsets), 
inflammation (high sensitivity C-reactive protein [hsCRP]), and an index of renal function, 
cystatin C, and obtain data on their prognostic significance. cFLC levels in patients with 
STEMI were compared to levels in patients with stable coronary artery disease (‘disease 
controls’) and healthy subjects. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
5 
 
 
Methods 
 
Cross-sectional analysis 
cFLC levels were compared between 48 patients with ST-elevation MI (STEMI) and age- 
and sex-matched control groups: (i) 40 patients with stable coronary artery disease (CAD) 
and (ii) 37 healthy volunteers. The STEMI was diagnosed according to the European Society 
of Cardiology definition[25] and treated with primary percutaneous coronary intervention. 
Median troponin T values were 2.6 [1.30-5.68] μg/l (normal <0.01 μg/l). CAD was confirmed 
during elective coronary angiography, with no hospital admissions for ≥3 months. Exclusion 
criteria comprised infectious disease, inflammatory disorders and their treatment [including 
steroids and non-steroidal anti-inflammatory drugs], cancer, haemodynamically significant 
valvular heart disease, atrial fibrillation, renal failure and hormone replacement therapy. 
Additionally, no STEMI patients had a history of previous MI or left ventricular dysfunction.  
 
Longitudinal analysis 
In patients with STEMI plasma markers were measured at four time-points: day 1 (during the 
first 24 h after primary percutaneous coronary intervention (PCI)), day 3, day 7 and day 30. 
Eighteen patients did not complete follow-up due to withdrawal of consent or death. Thirty 
patients with cFLC levels available for all time points were included in the longitudinal 
analysis. 
 
Blood samples were collected from all participants and plasma stored at -70 ºC for batched 
analysis. Fresh blood was used for haematological analysis and quantification of monocyte 
subsets as described previously.[26, 27] 
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All study patients received standard treatment according to current guidelines.[25] The study 
was performed in accordance with the Helsinki declaration and was approved by the 
Coventry Research Ethics Committee. All participants provided written informed consent. 
 
Outcome analysis 
The prognostic significance of cFLC levels in STEMI was assessed with the primary 
outcome defined as a composite of ‘death, admission for ACS, newly diagnosed HF or HF 
related hospital admission or new PCI’ and the secondary end-point of ‘need for new PCI’ 
during follow up. 
 
Flow cytometry  
Monocytes and their subsets, as cellular markers of innate immunity and inflammation, were 
analysed by flow cytometry (BD FACSCalibur
TM
 flow cytometer, Becton Dickinson [BD], 
Oxford, UK) as previously described.[26, 27] Absolute count of monocyte subsets was 
established using mouse anti-human monoclonal fluorochrome conjugated antibodies anti-
CD16-Alexa Fluor 488 (clone DJ130c; AbD Serotec,Oxford, UK), anti-CD14-PE 
(cloneM/P9; BD), and anti-CCR2- APC (clone 48607, R&D Systems, Abingdon, UK) in 50 
μL of fresh EDTA anticoagulated whole blood in TruCountTM tubes (BD). Monocyte subsets 
were defined as CD14++CD16CCR2+ (classical), CD14++CD16+CCR2+ (intermediate) and 
CD14+CD16++ CCR2 (non-classical) in accordance with contemporary nomenclature. 
 
Plasma markers 
cFLC concentrations were determined using the Combylite
TM
 assay on the SPAPLUS® 
turbidimeter (The Binding Site Group Ltd, Birmingham, UK, 95% percentile reference range 
9.3-43.3mg/L (determined in serum samples), following the manufacturers recommendations. 
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[23] Combylite quantifies the combined FLC κ and FLC λ concentration in a single 
assay.[28] Cystatin C (The Binding Site Group Ltd, reference range 0.56-0.99 mg/L) and 
hsCRP (Roche/Hitachi Tina-quant® cardiac C-reactive protein high sensitive, Switzerland, 
reference range 0-3mg/L) concentrations were measured on the BNII
TM
 nephelometer 
(Siemens, Germany) following the manufacturers recommendations. 
 
Power calculation 
As there are no data for FLC, we calculated that minimum number of participants required to 
achieve 80% power to detect changes of 0.5 standard deviation in non-classical monocytes 
subsets was n=35 for the cross-sectional study and n=25 for the longitudinal study.  
 
Statistical analysis 
Normal data are presented as mean [standard deviation - SD] non-normal data are shown as 
median [interquartile range, IQR]. Cross-sectional comparisons between the three study 
populations were made using a chi-square test (for categorical variables), one way analysis of 
variance (ANOVA) with Tukey post-hoc test (for normal data) or Kruskal Wallis test with 
Dunn’s post-hoc test (for non-normal data). Longitudinal analysis was performed using 
repeated measures ANOVA with Bonferroni adjustment (normal data) or Friedman test with 
Dunn’s post-hoc test (non-normal data). Only STEMI patients who had blood samples for all 
time-points were included in the longitudinal analysis. For STEMI patients, correlation 
coefficients were calculated by Spearman tests (non-normal data). Linear regression analysis 
was used to establish predictive value of cFLC for LVEF measured 6-weeks post-STEMI. 
Predictive value of the cFLC for the study outcome parameters in STEMI was assessed using 
a Cox regression analysis and the Kaplan-Meier log-rank test. In the multivariable Cox 
regression analysis adjustments were made for parameters showing significant predictive 
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value (or a strong trends towards significant predictive value) in multivariate analysis. 
Additionally the multivariable Cox regression analysis included cystatin C (a marker of renal 
function) and troponin concentrations (a marker of myocardial damage). Data analysis was 
carried out using SPSS 18.0 (SPSS Inc, Chicago, IL, USA) and a two-sided p-value of <0.05 
was considered statistically significant. 
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Results 
 
The 3 patient groups were well matched for age, gender, current blood pressure level and 
body mass index, creatinine and estimated glomerular filtration rate (eGFR) (Table 1). 
Patients with acute STEMI had increased counts of monocytes and neutrophils compared to 
other groups (p<0.001). Healthy controls included a smaller proportion of smokers than other 
groups (p<0.001). 
 
Increased hsCRP and Cystatin C levels were evident in patients with acute STEMI compared 
to the control groups (Table 1). No significant difference was observed in cFLC values at day 
1 between STEMI patients and the two control groups. 
 
In acute STEMI, cFLC correlated with cystatin C (Spearman r=0.55, p=0.00009), and 
negatively correlated with counts of ‘classical’ CD14++CD16– monocyte counts (Spearman 
r=-0.55, p=0.00005). There was no correlation between cFLC and other monocyte subsets, 
troponin T, or CRP. Absolute values of the monocyte subsets in this study population have 
been reported previously.[27] 
 
Longitudinal analysis 
In STEMI patients there was a significant increase in cFLC during the period of observation 
with highest values seen on day 7 post MI (p<0.001 vs. day 1) with increased levels 
persisting at day 30 (p<0.001 vs. day 1) (Table 2 Figure 1). hsCRP concentrations peaked on 
day 3 of the MI followed by their gradual reduction to the levels seen in controls (p<0.001). 
Cystatin C concentrations were significantly increased (as compared to day 1) values on day 
3 (p=0.006) and day 30 (p=0.002), but not on day 7 (p>0.05).  
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Outcome analysis 
Sixteen primary outcome events were recorded during a (median) follow up period of 39 [19-
43] months (Table 2). Cox regression analysis, cFLC levels at presentation in acute STEMI 
were not predictive of the primary outcome (Hazard Ratio 1.03 [0.98-1.09], p=0.29). On 
Kaplan-Meier analysis, high (>median levels, 24 [20-34] mg/L) cFLC levels were not 
predictive of the primary outcome (log-rank test p=0.23). Nine secondary outcome events of 
new PCI occurred during a median follow up of 40 [37-44] months. cFLC concentrations 
were 23 [19-30] mg/L in patients free from new PCI and 30 [27-41] mg/L in patients who 
had new PCI [p=0.033, Mann-Whitney test]. On univariate Cox regression analysis, cFLC 
concentrations were associated with an increased risk for new PCI and remained predictive 
on multivariate analysis (Table 4). On Kaplan-Meier analysis, there was a trend for high 
cFLC levels to be related new PCI which did not reach statistical significance (log-rank test, 
p=0.066) (Figure 2). 
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Discussion 
 
This pilot study provides the first analysis of cFLC in patients with STEMI. During acute 
phase of the disease cFLC values were similar to those in stable CAD and healthy 
individuals. However cFLC levels showed a relatively small but significant increase during 
the follow up period with peak concentrations determined on day 7 and were still increased 
on day 30. Secondly, cFLC concentrations measured at presentation were associated with an 
increased risk for new PCI even on multivariate analysis. 
 
Median cFLC concentrations remained within the normal range even at day 7 post MI; 
however the analysis matched the data from individual patients and showed a highly 
statistically significant and consistent increase in most patients, as shown in figure 1. The 
observed changes can involve several mechanisms. First, they could be reflective of 
progressive dysfunction of the adaptive immune system soon after MI onset (i.e., B-cell 
activation and proliferation).[15] For example, Zouggari et al. have shown that mobilization 
of proinflammatory monocytes following experimental acute MI was mediated by activity of 
mature B lymphocytes (ie, their CCL7 production).[29] The animal experiments were further 
supported by evidence from patients with acute MI where high plasma levels of CCL7 and 
BAFF in patients with acute MI were associated with increased risk of death or recurrent 
MI.[29]  Second, raised cFLC could be due to their delayed removal from circulation. Indeed, 
our study shows a significant correlation between cFLC and cystatin C, a marker of kidney 
dysfunction. However it is unlikely that renal impairment is the sole explanation of cFLC 
elevation, and the changes reflect different dynamics in the biomarkers. For instance, on day 
7 of STEMI when highest cFLC levels were noted, cystatin C concentrations on day 7 were 
not significantly different from those on day 1 of STEMI. No correlation was found between 
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cFLC and troponin levels suggesting that the extent of myocardial damage may not be of 
paramount importance for cFLC production. Of note, cystatin C and BNP levels fall by 30 
days, whilst cFLC levels remain elevated. This may indicate a relation of cFLC to longer-
term processes related to myocardial healing/remodelling. 
 
As expected, there was no significant correlation between cFLC, which is a marker of activity 
of the adaptive immune system and hsCRP, a liver-derived marker of inflammatory responses 
related to the innate immune response.[20] However there was a significant negative 
correlation between cFLC and counts of ‘classical’ CD14++CD16- monocytes, a cellular 
marker of innate immunity. 
 
Despite their primary role in innate immune responses, monocytes have diverse functions 
being involved in numerous inflammatory and reparative responses.[30] FLC can bind 
directly to human monocytes and can induce mast cell degranulation and neutrophil 
activation. [31, 32] Monocytes are diverse and include several subsets with specific 
functions, of which ‘classical’ monocytes are characterised by high phagocytic activity and 
proinflammatory phenotype.[22, 26, 33] Although the study does not provide direct insight 
into the mechanisms of the association between the cFLC and ‘classical’ monocytes the 
observed negative correlation between these biomarkers could potentially be related to 
specific capacity of this monocyte subset to bind cFLC. However it is unclear whether these 
interactions simply represent a mode of elimination of cFLC from the circulation or they have 
functional consequences for monocyte activity.  
 
The function and clinical consequences of the cFLC rise post-STEMI remains unclear. 
Immune abnormalities are known to play an important role in atherosclerosis and cFLC 
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upregulation post STEMI may reflect arterial processes within unstable coronary artery 
lesions characteristic of acute coronary syndromes. Of note, cFLC levels are predictive of 
future need for repeat PCI and thus could be related to accelerated disease progression in 
ACS patients already in a ‘high risk’ category (eg, post STEMI). The association remains 
significant even after adjustment for status of renal function and inflammation as assessed by 
hsCRP. The mechanistic insight(s) in these associations is still to be provided, but it is likely 
that cFLC could be implicated in immune responses related to progression of atherosclerosis, 
particularly in settings post ACS events. These data accord with previous evidence of 
predictive role of high cFLC concentrations in general population.[23] 
 
Limitations 
This pilot study is relatively small and has limited power to establish the prognostic role of 
cFLC in STEMI, but allows hypothesis generation. Also, our data provide only limited 
information on possible mechanisms related to changes in cFLC post-MI and specifically 
designed pathophysiological studies will be required to address the issue.  
 
In conclusion, cFLC levels increase during STEMI with peak values on day 7 after 
presentation and on multivariate analysis, predict the need for future PCI. The precise 
pathophysiological and clinical significance of this phenomenon remains unclear but may 
reflect post-STEMI inflammatory responses or renal reserve changes in these patients, which 
deserve further exploration. 
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Figure 1. Dynamics of the cFLC in STEMI 
cFLC, combined free light chains. 
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Figure 2. Predictive value of the above median cFLC levels for the secondary outcome 
(Kaplan-Meier analysis) 
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Table 1. Characteristics of the study groups 
 STEMI 
(n=48) 
Stable CAD 
(n=40) 
Healthy 
(n=37) 
p 
Demographic and clinical characteristics 
Age, years 58 [12] 60 [11] 60 [14] 0.54 
Male gender, n [%] 41 [85] 33 [83] 31 [84] 0.93 
Systolic BP, mmHg 132 [18] 133 [15] 128 [17] 0.74 
BMI, kg/m
2
 30 [6] 29 [5] 27 [4] 0.30 
LVEF, % 54 [14] 67 [8] - 0.24 
Creatinine, mol/L 92 [19] 90 [18] 78 [17] 0.26 
eGFR, ml/min/1.73m
2
 75 [15] 73 [14] 83 [10] 0.34 
Hypertension, n [%] 23 [48] 20 [50] 5 [14] 0.001 
Diabetes, n [%] 16 [33] 8 [20] 0 0.001 
COPD, n [%] 3 [6] 3 [8] 0 0.26 
Smoking, n [%] 28 [58] 17 [43] 1 [3] <0.001 
Medications 
Aspirin, n [%] 48 [100] 36 [90] 5 [14] <0.001 
Clopidogrel, n [%] 48 [100] 20 [50] 0 <0.001 
B-blockers, n [%] 33 [69] 27 [68] 0 <0.001 
ACEI/ARA, n [%] 43 [90] 29 [73] 4 [11] <0.001 
Statins, n [%] 46 [96] 34 [85] 5 [14] <0.001 
Blood leucocytes 
WBC, 10
3
 per L 10.8 [3.1]*† 6.6 [1.8] 5.9 [1.3] <0.001 
Neutrophils, 10
3
 per L 8.1 [2.9]*† 3.9 [1.2] 3.6 [1.1] <0.001 
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Lymphocytes, 10
3
 per L 1.7 [0.7] 2.0 [0.6] 1.8 [0.7] 0.24 
Total monocytes, per L 952 [375]*† 599 [165] 514 [196] <0.001 
CD14++CD16- monocytes, 
per L 
765 [322]*† 494 [146] 422 [169] <0.001 
CD14++CD16+ monocytes, 
per L 
98 [30-161] 35 [22-50] 27 [9-54] <0.001 
CD14+CD16++ monocytes, 
per L 
61 [40-89] 56 [42-82] 48 [35-62] 0.069 
Platelets, 10
3
 per L 266 [98] 226 [69] 254 [67] 0.094 
Plasma biomarkers  
cFLC, mg/L 26 [19-32] 24 [20-34] 25 [21-34] 0.70 
Cystatin C, mg/L 1.06 [0.25]† 1.12 [0.29] 0.95 [0.15] 0.008 
hsCRP, mg/L 8.3 [1.9-17]*† 1.5 [0.8-3.3] 1.0 [0.6-2.1] <0.001 
 
*p<0.05 vs. stable coronary artery disease; †p<0.05 vs. healthy controls; ACEI, angiotensin 
converting enzyme inhibitor; ARA, angiotensin receptor antagonists; BMI, body mass index, 
BNP, brain natriuretic peptide; CAD, coronary artery disease; COPD, chronic obstructive 
pulmonary disease; eGFR, estimated glomerular filtration rate; cFLC, combined free light 
chains; hsCRP, high sensitivity C-reactive protein; LVEF, left ventricular ejection fraction; 
WBC, whole blood count. Data are presented as mean [SD] for normally distributed variables 
and median [IQR] for non-normally distributed variables. 
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Table 2. Longitudinal analysis of the study parameters. 
N=30 Day1 Day3 Day7 Day 30 P value 
cFLC, mg/L 24 [19-29]*†‡ 25 [20-32] 28 [22-35] 27 [22-34] 0.00000008 
Cystatin C, mg/L 1.01 [0.22]*‡ 1.08 [0.17] 1.06 [0.18] 1.09 [0.22] 0.001 
hsCRP, mg/L 5.9 [1.7-12]*‡ 16.9 [5.3-41]†‡ 4.4 [1.6-11]‡ 1.3 [0.6-2.7] 0.0000000003 
‘Classical’ 
CD14++CD16- 
monocytes, per L 
810 [58]‡ 785 [59]‡ 712 [63] 557 [31]* < 0.0001 
 
*p<0.05 vs. day 3, †p<0.05 vs. day 7; ‡p<0.05 vs. day 30. cFLC, combined free light chains; 
hsCRP, high sensitivity C-reactive protein. 
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Table 3. Characteristics of patients with and without the primary outcome event 
 Primary outcome event occurred p 
 Yes 
(n=16) 
No 
(n=32) 
Demographic and clinical characteristics 
Age, years 64 [11] 54 [11] 0.006 
Male gender, n [%] 15 [94] 26 [81] 0.25 
Systolic BP, mmHg 128 [15] 135 [20] 0.48 
BMI, kg/m
2
 26 [4] 32 [6] 0.049 
LVEF, % 46 [12] 56 [14] 0.039 
Creatinine, mol/L 100 [23] 88 [15] 0.062 
eGFR, ml/min/1.73m
2
 70 [17] 77 [14] 0.16 
Hypertension, n [%] 9 [56] 14 [44] 0.41 
Diabetes, n [%] 7 [44] 9 [28] 0.28 
COPD, n [%] 0 3 [9] 0.21 
Smoking, n [%] 6 [38] 22 [69] 0.04 
Medications 
Aspirin, n [%] 16 [100] 32 [100] 1.00 
Clopidogrel, n [%] 8 [50] 15 [47] 0.84 
B-blockers, n [%] 11 [69] 22 [69] 1.00 
ACEI/ARA, n [%] 13 [81] 30 [94] 0.18 
Statins, n [%] 15 [94] 31 [97] 0.61 
Plasma biomarkers 
cFLC, mg/L 26 [21-38] 25 [19-31] 0.42 
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Cystatin C, mg/L 1.05 [0.89-1.15] 0.96 [0.86-1.16] 0.33 
hsCRP, mg/L 4.6 [1.2-9.6] 9.1 [2.6-21.3] 0.14 
ACEI, angiotensin converting enzyme inhibitor; ARA, angiotensin receptor antagonists; 
BMI, body mass index, BNP, brain natriuretic peptide; CAD, coronary artery disease; COPD, 
chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; cFLC, 
combined free light chains; hsCRP, high sensitivity C-reactive protein; LVEF, left ventricular 
ejection fraction; WBC, whole blood count. Data are presented as mean [SD] for normally 
distributed variables and median [IQR] for non-normally distributed variables.
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Table 4. Cox regression analysis of the predictive value of cFLC for new PCI. 
Parameter Hazard ratio [95% confidence interval] p value 
Univariate analysis 
cFLC, mg/L 1.10 [1.02-1.19] 0.018 
Cystatin C, mg/L 3.65 [0.30-43.7] 0.31 
hsCRP, mg/L 0.86 [0.73-1.01] 0.065 
Age, years 1.01 [0.95-1.07] 0.77 
Gender 0.04 [0.00-88.7] 0.41 
Troponin, ng/mL 1.06 [0.88-1.27] 0.53 
Multivariate analysis 
cFLC, mg/L
*
 1.10 [1.02-1.19] 0.019 
cFLC, mg/L
†
 1.25 [1.02-1.52] 0.031 
cFLC, mg/L
‡
 1.76 [1.02-3.02] 0.041 
 
cFLC, combined free light chains; hsCRP, high sensitivity C-reactive protein. 
*Adjusted for age, cystatin C and hsCRP; 
†Adjusted for age, cystatin C, hsCRP and troponin. 
‡ 
Adjusted for age, cystatin C, hsCRP, troponin and left ventricular ejection fraction
 
